Legend Biotech announced that China’s National Medical Products Administration has formally accepted its New Drug Application for ciltacabtagene autoleucel. This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myeloma who have received 3 or more prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug, the company said in a statement. Ying Huang, Chief Executive Officer of Legend, said: “Meeting medical needs and serving patients around the world has always been the goal of Legend Biotech’s innovative research and development. Cilta-cel has been approved for marketing in the United States and Japan and has received conditional marketing authorization in Europe. We look forward to the possibility of providing a new treatment option for appropriate patients with relapsed and refractory multiple myeloma in China.”